Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBT Margin: 2012-2025

Historic EBT Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -123.42%.

  • Enanta Pharmaceuticals' EBT Margin rose 7638.00% to -123.42% in Q3 2025 from the same period last year, while for Sep 2025 it was -127.90%, marking a year-over-year increase of 4625.00%. This contributed to the annual value of -127.90% for FY2025, which is 4625.00% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its EBT Margin stood at -123.42% for Q3 2025, which was down 24.02% from -99.52% recorded in Q2 2025.
  • Enanta Pharmaceuticals' EBT Margin's 5-year high stood at -99.52% during Q2 2025, with a 5-year trough of -211.37% in Q1 2023.
  • Its 3-year average for EBT Margin is -160.99%, with a median of -160.45% in 2025.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' EBT Margin slumped by 10,888bps in 2021, and later soared by 7,638bps in 2025.
  • Enanta Pharmaceuticals' EBT Margin (Quarterly) stood at -109.05% in 2021, then slumped by 1,399bps to -123.04% in 2022, then slumped by 6,597bps to -189.02% in 2023, then soared by 5,513bps to -133.89% in 2024, then soared by 7,638bps to -123.42% in 2025.
  • Its last three reported values are -123.42% in Q3 2025, -99.52% for Q2 2025, and -160.45% during Q1 2025.